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• In AML with normal cytogenetics, age, response to induction, and FLT3-ITD allow for 
an estimate of outcome after allogeneic HSCT in CR1 
• Neither variation of classical transplant techniques, nor  development of cGvHD 
outweighs the negative impact of FLT3-ITD 





Patients with cytogenetically normal acute myeloid leukemia (CN-AML) can be subdivided 
by molecular mutations. However, data on the influence of combinations of different 
aberrations on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) is 
limited. Therefore, we performed a retrospective registry analysis on 702 adults with CN-
AML undergoing HSCT in first complete remission (CR). Patients were grouped according 
to presence or absence of NPM1 mutations (NPM1mut) and FLT3 internal tandem 
duplications (FLT3-ITD). Double negative patients were evaluated for mutations of the 
CCAAT/enhancer binding protein α gene (CEBPα). The influence of genotypes on relapse, 
non-relapse mortality, leukemia-free survival (LFS) and overall survival (OS), and a 
prognostic classification combining NPM1/FLT3-ITD profile and classical risk factors were 
calculated. 2y-OS from HSCT was 81±5% in NPM1mut/FLT3wt (n=68), 75±3% in
NPM1
wt/FLT3wt (n=290), 66±3% in NPM1mut/FLT3-ITD (n=269) and 54±7% in 
NPM1
wt
/FLT3-ITD (n=75; p=0.003). Analysis of CEBPα among patients with NPM1wt/FLT3wt
revealed excellent results both in patients with CEBPαmut (n=13, 2y-OS:100%), and with a 
triple negative genotype (n=138, 2y-OS:77±3%). In a Cox-model of predefined factors, 
older age, presence of FLT3-ITD and >1 course of chemotherapy to reach CR were 
associated with inferior outcome. 2y-OS/LFS were 88±3%/79±4% in patients without any, 
77±2%/73±3% with one, and 53±4%/50±4 with>=2 risk factors (p=0.002 for LFS, p=0.003 
for OS). Hence, FLT3-ITD proofed to be the decisive molecular marker for outcome after 
HSCT for CN-AML in CR1, regardless of NPM1 mutational status, variations of transplant 
protocols, or development of GvHD. Age, FLT3-ITD and response to induction 
chemotherapy allow for a prognostic risk classification. 





Allogeneic hematopoietic stem cell transplantation (alloHSCT) offers a strong antileukemic  
effect in  acute myeloid leukemia (AML), although the benefit in terms of overall survival is 
compromised by non-relapse mortality (NRM).1 In first complete remission (CR1), the 
indication for alloHSCT is frequently based on genetic risk factors. In general, 
transplantation is recommended for patients with unfavorable cytogenetics, and 
discouraged for patients with favorable cytogenetic aberrations, whereas data are less clear 
in the intermediate cytogenetic subgroup.2;3;3
In patients with intermediate cytogenetics, and particularly cytogenetically normal AML (CN-
AML), molecular aberrations play a decisive role in prognosis.
2;4-7
 Therefore, international 
guidelines recommend testing for the two most frequent molecular markers (i.e., the 
mutation of the nucleophosmin1 gene, NPM1mut, and internal-tandem duplication of the 
fms-related tyrosine kinase 3 gene, FLT3-ITD), as well as the mutations of the 
CCAAT/enhancer binding protein α gene (CEBPα), as part of routine diagnostics in newly 
diagnosed AML.
2
  Among other factors, the indication for alloHSCT in CN-AML achieving 
CR is frequently based on the molecular profile, in particular on the presence of an FLT3-
ITD, although data on the role of alloHSCT even in this particular subgroup remains 
controversial,5;8-11 and the negative prognostic value of this aberration is maintained in the 
allogeneic setting.12 Recent data suggests that the mutual interaction of co-occurring 
molecular aberrations, rather than one single aberration alone, might be decisive for clinical 
outcome. In particular, the prognostic significance of FLT3-ITD is thought to be modified by 
NPM1
mut.13-15 Nevertheless, it is not clear so far from clinical data, whether patient 
subgroups characterized by different combinations of molecular markers do have different 
outcomes after alloHSCT, since the numbers of transplanted patients in reported series are 
relatively small.
5;11;16
  With this background, the Acute Leukemia Working Party (ALWP) of 




EBMT performed a retrospective, registry based analysis, in order to provide data on risk 
factors and overall survival (OS) after alloHSCT in CR1 in large, molecularly defined 
subgroups of patients with CN-AML.  
 




Patients and Methods 
Inclusion criteria and data collection 
EBMT is a voluntary organization including more than 500 transplantation centers, that are 
required to file annual follow-up reports on all consecutive HSCT, based on patients’ written 
informed consent in accordance with the Declaration of Helsinki. After approval by the 
Acute Leukemia Working Party board, adult patients with de novo AML were selected from 
this database according to the following criteria: (1) first alloHSCT in CR1 (excluding CR 
with incomplete recovery, CRi) between 2006 and 2012 (2) HLA-identical related or at least 
7/8 antigen (HLA A, B, DR, DQ) matched unrelated donor (RD/MUD) (3) normal karyotype 
and (4) available information on the presence or absence of NPM1
mut
 and FLT3-ITD at time 
of diagnosis. Cytogenetics and molecular genetics were performed by the referring 
institutions according to local standards. 
Data extracted from the database and completed by transplant centers upon additional 
request included age, gender, donor relationship and HLA compatibility, conditioning 
regimen, graft source, graft-versus-host disease (GvHD) prophylaxis, disease response, 
incidence of GvHD and relapse after HSCT, survival status, date and cause of death, and 
last follow-up. In order to ensure quality of the data,  physicians reviewed submitted data 
and made personal contact with reporting centers to clarify doubtful information. 
Definitions and statistics 
Remission and relapse,2 conditioning intensity17 and Graft-versus-Host Disease (GvHD)18
were defined and classified as described.  
The probabilities of acute and chronic GVHD, NRM, and relapse were calculated by using 
the cumulative incidence estimator to accommodate competing risks. For NRM, relapse 
was the competing risk, and for relapse, the competing risk was NRM. For acute and 




chronic GVHD, death without the event was the competing risk. The Gray test was used for 
comparisons. Overall survival (OS) and leukemia free survival (LFS) were calculated from 
date of HSCT, using Kaplan-Meier estimates. For all prognostic analyses, continuous 
variables were categorised and the median was used as a cut-off point. Chronic GvHD was 
included as time dependant variable. A Cox proportional hazards model was used for 
multivariate regression. Variables differing in term of distribution between the groups and 
factors conceptually important were included in the model. Results are expressed as 
hazard ratio (HR) with 95% confidence interval (CI).  
All tests were two-sided. The type I error rate was fixed at 0.05 for determination of factors 
associated with time-to-event outcomes. SPSS 19.0 and R 3.0.1 software packages were 
used. 





Information on molecular markers was available in 702 patients. Data on 15 patients 
reported earlier12 were updated for the present analysis, whereas results in 687 patients 
had not been analyzed before. Median age was 51 years, 80% received PBSC grafts. 55% 
each had related, 45% had unrelated (8/8 match, n=49, 10/10 match, n=225, 9/10, n=49) 
donors. Conditioning was myeloablative (MAC) in 47%, and reduced (RIC) or non-
myeloablative (NMA) in 53%. Based on the presence of NPM1mut and FLT3-ITD at 
diagnosis, patients were grouped into four different genotypes: NPM1wt/Flt3wt (n=290, 41%), 
NPM1
mut/FLT3wt (n=68, 10%), NPM1wt/FLT3-ITD (n=75, 11%), and NPM1mut/FLT3-ITD 
(n=269, 38%). Molecular subgroups were well balanced with respect to the majority of 
characteristics. However, imbalances were observed concerning the interval from diagnosis 
to CR (nine days longer in the NPM1wt groups) and to alloHSCT (ten days longer in FLT3wt
groups), the number of induction courses to reach CR1 (higher in the NPM1wt/FLT3-ITD 
group), the year of transplantation (one year earlier in the FLT3wt groups), and the intensity 
of the conditioning (more MAC in the FLT3-ITD groups; cf. Table 1 for detailed patient 
characteristics).  
Relapse and non-relapse mortality after alloHSCT 
Concerning cumulative incidence of relapse (CIR), the molecular subgroups differed 
significantly according to FLT3 mutational status, with patients with FLT3-ITD showing a 
higher CIR (26±3% and 34±6% at 2 years in patients with and without concomitant 
NPM1
mut) as compared to patients lacking FLT3-ITD (2-year CIR: 16±3% and 14±2% in 
patients with and without NPM1mut, global p-value between FLT3-ITD and FLT3wt: 0.0009). 
In contrast, the presence or absence of NPM1mut did not significantly influence CIR in both 




FLT3-ITD and FLT3wt. Molecular subgroups did not show any influence on NRM (global p-
value: 0.75;, Figure 1, supplement  Table 1).   
In the multivariate model, FLT3-ITD (HR:2.23, 95%CI:1.44-3.46, p=0.0003) and the number 
of courses of induction chemotherapy to reach CR1 (HR:1.50, 95%CI:1.02-2.22, p=0.04) 
showed significant influence on CIR, whereas variations of the transplant procedure such 
as donor choice, (sibling versus unrelated), intensity of the conditioning, TBI and use of 
ATG had no influence. Younger age (HR:3.42, 95%CI:1.98-5.91, p<0.0001), RIC (HR:0,.57, 
95%CI:0.34-0,97, p=0.04) and a shorter interval between achievement of CR and date of 
alloHSCT (HR:0.55, 95%CI:0.34-0.90, p=0.02), but not molecular subtype, intensity of the 
conditioning, or donor type (including 1 AG mismatched unrelated donors) were protective 
against NRM (Table 2). 
GvHD 
Cumulative incidence of aGvHD grade 2-4 and cGvHD was 29±2% and 40±2%, 
respectively, with no differences among molecular subgroups (global p-value: 0.23 for 
aGVHD, 0.27 for cGvHD, see supplement Table 1 for details). No significant influence of 
cGvHD on CIR could be detected either in the entire cohort or within molecular subgroups 
(p=0.30/0.20 among FLT3wt +/- NPM1mut, 0.90/0.96 among FLT3-ITD+/- NPM1mut), when 
including cGvHD into the model as time-dependent variable. 
Overall survival and leukemia-free survival after alloHSCT 
With a median follow-up of 26 months from transplantation among survivors, 2y-OS and 
LFS for the entire cohort was 70±2% and 64±2%, respectively. Molecular subgroups had a 
strong influence on outcome (global p-value 0.003 for OS, 0.002 for LFS), with the best 




group (2y-OS:81±5% LFS:75±5%). Notably, 





wt/FLT3wt patients showed similarly favorable results (2y-OS:75±3% LFS:70±3%), 
whereas outcome was clearly inferior in patients harboring an FLT3-ITD (2y-
OS:66±3%/LFS:60±7% in NPM1mut/FLT3-ITD and 54±7%/48±7% in NPM1wt/FLT3-ITD). 
Thus, in the presence of FLT3-ITD, NPM1mut showed a positive trend, but did not 
significantly alter outcome results (p=0.15 for OS, p=0.13 for LFS, respectively; Figure 2A, 
LFS, B, OS; supplement Table 1).   
Using a Cox model for multivariate analysis, the presence of an FLT3-ITD (HR:1.85, 
95%CI:1.29-2.66, p=0,001 for OS, HR: 1,77, 95%CI: 1,27-2,48, p=0,001 for LFS) and age 
above the median (HR:2.54, 95%CI:1.77-3.66 , p<0,0001 for OS, HR:1.90, 95%CI:1.36-
2.66 , p=0.0002 for LFS) were the main risk factors for outcome. Further, the number of 
induction courses to reach CR1 was of borderline significance (HR:1.37, 95%CI:0.99-1.91, 
p=0.06 for OS, HR:1.43, 95%CI:1.06-1.95, p=0.02 for LFS; Table 2). As with CIR, outcome 
was not influenced either by modifications of the transplant regimen (including donor type, 
donor match and intensity of the conditioning)  or development of GvHD.  





To further subdivide the NPM1wt/Flt3wt cohort, the role of the mutational status of CEBPα
was analyzed in 151 informative patients. Thus, 2y-OS/LFS among triple negative patients 
(n=138, 91 %) was 77±3%/72±3%, whereas 13 patients (9%) harboring a CEPBα  mutation 
had an OS/LFS of 100%/92±3% . 
Prognostic risk classification 
Based on the three independent risk factors (FLT3-ITD, age above the median, >1 
induction course to reach CR1), a prognostic classification for outcome of CN-AML after 




alloHSCT was developed. Outcome parameters were significantly influenced by the score 
(none vs. one vs. two or three factors; p=0.003 for OS, 0.002 for LFS, 0.0002 for CRI, 0.01 
for NRM; Table 3; Figure 3). The classification was then validated in an independent cohort 
of an earlier study from our group.12 Although the two cohorts differed significantly with 
respect to important variables (e.g. intensity of the conditioning, year of transplant, length of 
follow up), the prognostic value of the classification was confirmed ( p<0.0001 for LFS, OS 
and CIR, respectively). 
  





In the largest study presented so far on the role of molecular markers in adult CN-AML 
patients undergoing alloHSCT in CR1, significant differences among genetic subgroups 
were observed. Thus, in addition to patient age, FLT3-ITD, but not NPM1
mut
, was identified 
as decisive factor for outcome. NRM and GvHD were not influenced by the molecular 
profile. By providing data on OS in high numbers of recently transplanted patients, including 
both related and unrelated donor, as well as reduced and myeloablative transplants, the 
results firmly establish, which outcome can be expected after alloHSCT in different 
molecular subgroups of CN-AML. Given the fact that leukemia relapse as the decisive 
event for outcome after allo HSCT for AML was observed at a median of <6 months from 
alloHSCT both after RIC and MAC transplants,19-21 a follow-up longer than 2 years seemed 
to be reasonable. Further, the data allowed for a prognostic classification of patients 
undergoing HSCT for CN-AML. 
Strict inclusion criteria and an extensive survey among participating centers, including 
repeated questionnaires and personal contacts, ensured high patient numbers and data 
quality. Nevertheless, the nature of a retrospective, registry-based study implicates 
limitations.  
First, EBMT registry only provides data on patients who in fact underwent alloHSCT. 
Therefore  we are not able to answer the question of whether or not alloHSCT should be 
offered to all patients diagnosed with CN-AML and one of the molecular subgroups defined 
here.  
Second, we could not determine the mutant/wildtype allele ratio (AR) of FLT3-ITD, nor the 
insertion site of FLT3-ITD, in the majority of patients. Both variables have been described to 
play a major role for outcome after conventional therapy and alloHSCT, and also seemed to 




modify the role of other mutations, such as NPM1mut.16;22-24 However, heterogeneity, 
methodological problems and the relatively low sensitivity of most PCR assays, as well as a 
missing general agreement concerning a cutoff level for the FLT3-ITD/wildtype AR11;16;23-27
have prompted the suggestion to generally classify all non-APL FLT3-ITD cases as poor 
risk.
10;28
 Further, no role of  the mutant/wildtype AR on CIR after alloHSCT could be shown 
by the recent AML-SG study,11 and next generation sequencing revealed the presence of 
different FLT3-ITD clones within the same patient both at diagnosis and during the course 
of the disease.29;30 Therefore, and in accordance with several well accepted prognostic 
models3;5;31  and recent classification systems7 for CN-AML, we decided to limit our analysis 
to the general presence or absence of FLT3-ITD.  
Third, we don’t have data on other, recently identified mutations possibly modifying the 
prognostic role of both FLT3wt and FLT3-ITD patient subsets, such as TET2, DNMT3A,
ASXL1 and IDH1/2. The prognostic role and mutual interaction of these mutations is a 
matter of ongoing research,32 and the role of different genotypes might vary according to 
the applied therapy, as shown for high-dose daunorubicin.
7
 Further, integration of several 
mutations into a clinically based prognostic scoring system is difficult, as demonstrated in a 
recent study by the German AML-SG, where high numbers of missing data on concurrent 
mutations precluded the inclusion of these variables in a multivariable model on outcome.11
Hence, for the time being, the data in molecular subgroups, which are based on the two 
most frequent molecular markers, as well as the proposed prognostic classification, might 
be a reasonable tool to estimate the outcome after alloHSCT in CR1 in a given patient with 
CN-AML. 
The role of the general presence of FLT3-ITD for LFS and CIR even after alloHSCT has 
been shown previously for patients undergoing myeloablative conditioning for 
predominantly matched sibling transplants,
12
 although it had not been observed by 




others.9;33 Besides confirming the negative influence of FLT3-ITD in a larger cohort 
including unrelated transplants and RIC, and extending it to an analysis on OS, we also 
looked for variations within the transplant procedure to identify strategies for improvement 
in this high-risk cohort. However, when adjusting for confounding factors, neither an 
unrelated donor, modified intensity of the conditioning, nor the use of ATG or inclusion of 
TBI into the preparative regimen could be shown to cause a significant difference among 
patients with FLT3-ITD. Similarly, development of cGvHD did not significantly protect 
against relapse. Hence, it seems unlikely, that the negative prognostic value of FLT3-ITD 
might be abrogated by modification of the traditional components of the transplant 
procedure. This strongly argues in favor of the integration of innovative approaches into the 
transplant strategies. As an example, FLT3 inhibitors, which have been studied either as 
part of the induction treatment,34-36 as bridging to alloHSCT,(summarized in 28) or as 
maintenance after alloSCT, should be further evaluated in randomized trials in order to 





 defined a subgroup with excellent prognosis among patients 
with FLT3wt. In the context of alloHSCT, this is ascribed to the presence of a particular 
strength of the allogeneic immune response.38 In contrast, the previously described 
protective role of NPM1mut in patients bearing FLT3-ITD13-15 could not be unequivocally 
confirmed by our data. Hence, this co-occurrence might either play no major role after 
alloHSCT, or the influence of NPM1
mut
 might be limited to patients with a low FLT3-ITD/wild 
type AR.16;24 However, in a recent AML-SG study, no impact of a concurrent NPM1
mutation could be demonstrated either.11 Integrated genetic profiling data further revealed a 
modification of the prognostic role of FLT3-ITD by other mutations not evaluated in our 
study, e.g. TET2 or DNMT3A.7




Patients with a double negative genotype (NPM1wt/FLT3wt) were further characterized by 
presence or absence of CEBPα, the third molecular aberration generally recommended for 
testing in newly diagnosed AML.2 Accordingly, even triple negative patients (n=138) 
showed an excellent outcome after alloHSCT, although having been identified to bear an 
increased risk in earlier studies.
5
 This confirms data suggesting a potent Graft-versus-
Leukemia effect in this particular subgroup.39 Longer follow up might be required to confirm 
this observation, since this subgroup was the only one showing late relapses beyond 3 
years from HSCT. In contrast, the excellent outcome of 13 patients with NPM1wt/FLT3wt and 
mutated CEBPα should not be over interpreted, given low numbers and missing 
information, whether or not CEBPα mutation was bi-allelic.
40
In conclusion, our data allow for a reliable prognostic estimate of outcome in different, well 
defined molecular subgroups of patients with CN-AML after alloHSCT in CR1, with a 
remarkable impact of age and FLT3-ITD. Additional molecular features such as FLT3-ITD 
allelic burden or insertion site of FLT3-ITD,11;41 as well as the simultaneous search for co-
occurring and potentially interacting molecular markers might refine the accuracy of the 
estimate. The relevance of these additional characteristics should, however, be evaluated 
specifically in the setting of alloSCT, and in reliable numbers of patients. The study had not 
been designed to answer the question of whether or not patients with certain molecular 
subgroups should or should not undergo alloHSCT in CR1, nor can the findings be 
transferred to the entire patient population with newly diagnosed CN-AML. Nevertheless, 
the data might provide a basis for the decision between transplant and non-transplant 
consolidation strategies by giving a clear idea of the outcome to be expected after 
alloHSCT in a certain patient. In FLT3-ITD CN-AML, modifications of traditional transplant 
techniques did not improve outcome. Hence, studies evaluating the inclusion of innovative 
components, such as FLT3-inhibitors, are warranted.
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Legend to tables  
Table 1
Characteristics of NPM1/FLT3-ITD molecular subgroups among 702 patients 
undergoing allogeneic HSCT in first CR for AML with normal cytogenetics, as of 
molecular subgroups 
Abbreviations: CR1, first complete remission; HSCT, hematopoietic stem cell 
transplantation; ATG, anti.thymocyte globulin; UD, unrelated donor; BuCy, 
Busulfan/Cyclophosphamide; BuFlu, Busulfan/Fludarabin; CyTBI, Cyclophosphamide/total 
body irradiation; FluMel, Fludarabin/Melphalan; GvHD, graft-versus-host disease; CyA, 
Ciclosporin A; MTX, Methotrexate; MMF, mycophenolate mofetil 
*HLA identical sibling vs. unrelated donors 
** different subgroups of unrelated donors (10/10, 9/10, 8/8 AG matched)  
Table 2
Multivariate analysis of risk factors for 2-year outcome after allogeneic HSCT 
Abbreviations: RIC, reduced intensity conditioning, MAC, myeloablative conditioning, MUD, 
matched unrelated donor, HLA, human leucocyte antigen, CR1, first complete remission 
HSCT, HSCT, hematopoietic stem cell transplantation 





Prognostic score for 2-year outcome following allogeneic HSCT in CN-AML. 
 Presence of Flt3-ITD, age > median, and >1 course of chemotherapy to reach CR1 
were included as risk factors. 
Abbreviations: LFS, leukemia-free survival, SE, standard error, OS, overall survival CIR, 
cumulative incidence of relapse; NRM, non-relapse mortality   
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Characteristics of NPM1/FLT3-ITD molecular subgroups among 702 patients 
undergoing allogeneic HSCT in first CR for AML with normal cytogenetics, as of 
molecular subgroups 
Abbreviations: CR1, first complete remission; HSCT, hematopoietic stem cell 
transplantation; ATG, anti.thymocyte globulin; UD, unrelated donor; BuCy, 
Busulfan/Cyclophosphamide; BuFlu, Busulfan/Fludarabin; CyTBI, Cyclophosphamide/total 
body irradiation; FluMel, Fludarabin/Melphalan; GvHD, graft-versus-host disease; CyA, 
Ciclosporin A; MTX, Methotrexate; MMF, mycophenolate mofetil 
*HLA identical sibling vs. unrelated donors 
** different subgroups of unrelated donors (10/10, 9/10, 8/8 AG matched)  
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Multivariate analysis of risk factors for 2-year outcome after allogeneic HSCT 
Abbreviations: RIC, reduced intensity conditioning, MAC, myeloablative conditioning, MUD, 
matched unrelated donor, HLA, human leucocyte antigen, CR1, first complete remission 
HSCT, HSCT, hematopoietic stem cell transplantation 
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Prognostic score for 2-year outcome following allogeneic HSCT in CN-AML. 
 Presence of Flt3-ITD, age > median, and >1 course of chemotherapy to reach CR1 
were included as risk factors. 
Abbreviations: LFS, leukemia-free survival, SE, standard error, OS, overall survival CIR, 
cumulative incidence of relapse; NRM, non-relapse mortality  
 
 




Legend to figures 
Figure 1.
Cumulative incidence of relapse (CIR, A) and non-relapse mortality (NRM, B) after 
alloHSCT according to molecular subgroups 
Figure 2.  
Leukemia free survival (LFS, A) and overall survival (OS, B) according to molecular 
subgroups 
Figure 3.
Estimate of leukemia free survival (LFS, A) overall survival (OS, B,), cumulative incidence if 
relapse (CIR, C,) and non-relapse mortality (NRM, D,) after allogeneic HSCT in CN-AML, 
based on independent prognostic parameters (FLT3-ITD, age, and the number of induction 
courses to achieve CR).
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